NCT00107289 2026-03-13
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
14 trialsNCT07261241 2025-12-03
NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab
New Approaches to Neuroblastoma Therapy Consortium
Phase 2 Not yet recruiting
NCT04385277 2025-10-27
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Phase 2 Active not recruiting
NCT02378428 2025-05-13
MIBG
Nationwide Children's Hospital
Phase 2 Active not recruiting
NCT00253435 2023-04-10
N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma
Children's Hospital Los Angeles
Phase 2 Completed
NCT03561259 2023-02-16
OPTIMUM
Jubilant DraxImage Inc.
Phase 2 Unknown
NCT02035137 2022-06-08
N2011-01
New Approaches to Neuroblastoma Therapy Consortium
Phase 2 Completed
NCT00874614 2020-02-20
A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
Phase 2 Unknown
NCT01413503 2018-09-18
A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
University of California, San Francisco
Phase 2 Completed
NCT00960739 2016-08-08
MIITOP
Centre Oscar Lambret
Phase 2 Completed
NCT02771743 2016-05-24
Response-based Treatment of High-risk Neuroblastoma
Samsung Medical Center
Phase 2 Unknown
NCT00293319 2014-08-18
131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma
University of California, San Francisco
Phase 2 Completed
NCT00389766 2013-07-10
High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00013806 2005-06-24
CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study
National Center for Research Resources (NCRR)
Phase 2 Unknown